Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Chovatiya is also the founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, Illinois.
Transcript
Could you provide insights into the current clinical evidence supporting the use of oral JAK inhibitors for patients with AD, including efficacy, safety profiles, and potential long-term outcomes?
Whenever we're talking about any therapy, oral JAK inhibitors included, you want to give the good with the bad, the positive with the negative. So, I'll start with the good stuff.
When it comes to thinking about oral JAK inhibitors, particularly at their higher dosing—both abrocitinib and upadacitinib have a lower dose and a higher dose)—it's some of the highest efficacy we've really ever seen for atopic dermatitis therapies. There's been a variety of indirect comparisons in recent years using what's called a network meta-analysis to sort of compare across different trials. What ends up coming out every single time, typically, is that upadacitinib 30 milligrams and abrocitinib 200 milligrams tend to be your best shot at getting the highest rates of clearance and also getting the highest rates of itch response. The biologics then seem to slot right after that.
Now, what is going to be the trade-off? Well, with the higher doses of the oral JAK inhibitors, you're going to be thinking about some common safety adverse event issues. These aren't really the box warning issues; those are really quite rare, altogether, and there isn't any clear evidence of that being a reliable risk and adverse event in the real world. In the case of abrocitinib: nausea, dizziness, and things like that. In the case of upadacitinib: acne probably being the more common one. Across both of them, thinking about herpes simplex and herpes zoster–related exacerbations.
Now, the good news is that we've accumulated longer and longer and longer term data, and a bit of real-world data, which gives us some reassurance in a couple of regards. Number one, efficacy sure seems to hold up compared to what we've seen in clinical trials, and I can speak to that for my own practice. If anything, the lower dose of the JAK inhibitors probably performs even better than you may expect based on the clinical trials.
Now, when we think about safety, the good news is that the safety profile in the real world has also largely been reflected. If anything, there hasn't been necessarily a clear risk for some of the longer-term extension data. In the case of upadacitinib now, this is the longest we have, going up to about 5 years, of these events of being thromboembolism, major adverse cardiovascular event, and malignancy really being directly connected to the drug itself.
In fact, some nice analyses have shown that, when you sort of look at epidemiologic data in atopic dermatitis patients, generally, and then look at sort of the data from long-term extension arms of these drug studies, it looks like probably you're hovering right around the normal background rate of these events in the atopic dermatitis patient population in general.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen